Surrozen, Inc. Form 8-K Summary
Business Context and Reporting Period
Surrozen, Inc. filed a Form 8-K on August 9, 2023, under Item 2.02 to report the issuance of a press release announcing financial results for the quarter ended June 30, 2023. The filing identifies the company as an emerging growth company. The press release is furnished as Exhibit 99.1.
Financial Metrics
The filing text provided does not include the press release’s financial data. Revenue, net loss, cash flow, operating expenses, margins, debt, cash balance, liquidity, and other key metrics are therefore not clearly available from the filing text.
Material Changes Versus Prior Period
The filing does not provide comparative financial results or a clear description of material changes versus the prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
The filing text does not provide management guidance, outlook commentary, risk updates, contingencies, or unusual items. Item 2.02 information, including the referenced press release, is furnished rather than filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings under the Securities Act.
Key Facts to Verify
- Review Exhibit 99.1 for the quarter ended June 30, 2023 financial results.
- Verify reported cash, cash runway, operating expenses, net loss, and research and development spending.
- Check for any financing transactions, debt obligations, liquidity risks, or subsequent events discussed in the press release.
- Review management’s clinical-development outlook, guidance, and stated risks.
- Confirm the filing’s securities information: common stock trades under SRZN and redeemable warrants under SRZNW on The Nasdaq Capital Market.